| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Drs. Kieseier, Seifert, and Hartung), Karl-Franzens-Universität, Graz, Austria; and the Neuroimmunology Unit (Dr. Giovannoni), Institute of Neurology, Queens Square, London, UK.
Address correspondence and reprint requests to Dr. Bernd C. Kieseier, Department of Neurology, Karl-Franzens-Universität, Auenbruggerplatz 22, 8036 Graz, Austria.
Article Abstract
Matrix metalloproteinases (MMPs) degrade all protein components of the extracellular matrix. Functionally, they contribute to several different physiologic conditions, such as angiogenesis or bone remodeling, as well as pathologic conditions in humans, such as rheumatoid arthritis and tumor growth. MMPs seem to be important in the pathogenesis of inflammatory demyelinating diseases of the central and peripheral nervous system, especially in MS and in Guillain–Barré syndrome (GBS). Key mechanisms in the genesis of inflammatory demyelination, such as leukocyte recruitment, blood–brain barrier or blood–nerve barrier breakdown, myelin destruction, and release of disease-promoting cytokines, are considered to be MMP-dependent processes. In experimental autoimmune encephalomyelitis, an animal model of MS, and experimental autoimmune neuritis, an animal model of GBS, different synthetic inhibitors targeting MMP activity are able to suppress and even reverse ongoing disease. This evidence points to MMPs as new targets for treatment in inflammatory demyelination.
This article has been cited by other articles:
|
|
 |
|
  A. Goncalves DaSilva and V. W. Yong Matrix Metalloproteinase-12 Deficiency Worsens Relapsing-Remitting Experimental Autoimmune Encephalomyelitis in Association with Cytokine and Chemokine Dysregulation Am. J. Pathol., March 1, 2009; 174(3): 898 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Harris, J. A. Green, P. T. Elkington, and J. S. Friedland Monocytes infected with Mycobacterium tuberculosis regulate MAP kinase-dependent astrocyte MMP-9 secretion J. Leukoc. Biol., February 1, 2007; 81(2): 548 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Gran, N Tabibzadeh, A Martin, E S Ventura, J H Ware, G-X Zhang, J L Parr, A R Kennedy, and A M Rostami The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 688 - 697. [Abstract] [PDF]
|
|
|
|
|
|
E Fainardi, M Castellazzi, T Bellini, M C Manfrinato, E Baldi, I Casetta, E Paolino, E Granieri, and F Dallocchio Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 294 - 301. [Abstract] [PDF]
|
|
|
|
 |
|
 K. S. Moshal, U. Sen, N. Tyagi, B. Henderson, M. Steed, A. V. Ovechkin, and S. C. Tyagi Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway Am J Physiol Cell Physiol, March 1, 2006; 290(3): C883 - C891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Carmeli, M. Moas, S. Lennon, and S. K Powers High intensity exercise increases expression of matrix metalloproteinases in fast skeletal muscle fibres Exp Physiol, July 1, 2005; 90(4): 613 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matias-Roman, B. G. Galvez, L. Genis, M. Yanez-Mo, G. de la Rosa, P. Sanchez-Mateos, F. Sanchez-Madrid, and A. G. Arroyo Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium Blood, May 15, 2005; 105(10): 3956 - 3964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Kieseier, J. J. Archelos, and H.-P. Hartung Different Effects of Simvastatin and Interferon Beta on the Proteolytic Activity of Matrix Metalloproteinases Arch Neurol, June 1, 2004; 61(6): 929 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs Brain, February 1, 2004; 127(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Liuzzi, C. M. Mastroianni, T. Latronico, F. Mengoni, A. Fasano, M. Lichtner, V. Vullo, and P. Riccio Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia Brain, February 1, 2004; 127(2): 398 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jann, M. A. Bramerio, S. Beretta, S. Koch, C. A. Defanti, K. V. Toyka, and C. Sommer Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP Neurology, December 9, 2003; 61(11): 1607 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Seifert, B C Kieseier, S Ropele, S Strasser-Fuchs, F Quehenberger, F Fazekas, and H-P Hartung TACE mRNA expression in peripheral mononuclear cells precedes new lesions on MRI in multiple sclerosis Multiple Sclerosis, December 1, 2002; 8(6): 447 - 451. [Abstract] [PDF]
|
|
|
|
 |
|
 G. A. Rosenberg Matrix Metalloproteinases and Neuroinflammation in Multiple Sclerosis Neuroscientist, December 1, 2002; 8(6): 586 - 595. [Abstract] [PDF]
|
|
|
|
|
|
I. A. Scarisbrick, S. I. Blaber, C. F. Lucchinetti, C. P. Genain, M. Blaber, and M. Rodriguez Activity of a newly identified serine protease in CNS demyelination Brain, June 1, 2002; 125(6): 1283 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Brundula, N. B. Rewcastle, L. M. Metz, C. C. Bernard, and V. W. Yong Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis Brain, June 1, 2002; 125(6): 1297 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. D'Souza, B. Mak, and M. A. Moscarello The Up-regulation of Stromelysin-1 (MMP-3) in a Spontaneously Demyelinating Transgenic Mouse Precedes Onset of Disease J. Biol. Chem., April 12, 2002; 277(16): 13589 - 13596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Vaillant, M. G. Chiaramonte, A. W. Cheever, P. D. Soloway, and T. A. Wynn Regulation of Hepatic Fibrosis and Extracellular Matrix Genes by the Th Response: New Insight into the Role of Tissue Inhibitors of Matrix Metalloproteinases J. Immunol., December 15, 2001; 167(12): 7017 - 7026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. P. Lindberg, C. J. A. De Groot, L. Montagne, P. Freitag, P. van der Valk, L. Kappos, and D. Leppert The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis Brain, September 1, 2001; 124(9): 1743 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C S SETHI, T A BAILEY, P J LUTHERT, and N H V CHONG Matrix metalloproteinase biology applied to vitreoretinal disorders Br J Ophthalmol, June 1, 2000; 84(6): 654 - 666. [Full Text]
|
|
|
|
|
|
C. T. Bever Jr. and G. A. Rosenberg Matrix metalloproteinases in multiple sclerosis Neurology, October 22, 1999; 53(7): 1380 - 1380. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
